As salivary glands concentrate radio-iodine the radiation injury associated with 131I-therapy may result in sialoadenitis and xerostoma leading to a lasting impaired quality of life. Recently we reported about prostaglandin concentration changes as biochemical markers for radiation injury. Isoprostanes, a new family of prostaglandin-like compounds, have been demonstrated to be reliable markers for oxidation injury in vivo. Patients and methods: In this study we examined the levels of 8-epi-PGF2α, the major member of the isoprostane family in 24 patients undergoing 131I treatment in different doses for hyperthyroidism and differentiated thyroid cancer, 6 healthy sex and age-matched volunteers were monitored in parallel. Saliva (iso)prostaglandins were determined before 131I treatment, as well as 1,3,7,14,21, and 28 days, and 2,3, and 6 months after therapy. Results: 8-epi-PGF2α showed a significant 131I dose-dependent temporary increase. The alterations were comparable in all investigated patients and significantly higher in cigarette smokers. TXB2 and 6-oxo-PGF1α showed a dose-dependent increase too. TXB 2 was higher in cigarette smokers and 6-oxo-PGF1α lower as compared to non-smokers. Conclusion: These results clearly demonstrate a dose- and time-dependent tissue (TXB2, 6-oxo-PGF 1α) and oxidation injury (8-epi-PGF2α) after 131I-therapy in the salivary glands.
(Iso) Prostaglandins in saliva indicate oxidation injury after radioiodine therapy
PALUMBO, Barbara;PALUMBO, Renato;
2004
Abstract
As salivary glands concentrate radio-iodine the radiation injury associated with 131I-therapy may result in sialoadenitis and xerostoma leading to a lasting impaired quality of life. Recently we reported about prostaglandin concentration changes as biochemical markers for radiation injury. Isoprostanes, a new family of prostaglandin-like compounds, have been demonstrated to be reliable markers for oxidation injury in vivo. Patients and methods: In this study we examined the levels of 8-epi-PGF2α, the major member of the isoprostane family in 24 patients undergoing 131I treatment in different doses for hyperthyroidism and differentiated thyroid cancer, 6 healthy sex and age-matched volunteers were monitored in parallel. Saliva (iso)prostaglandins were determined before 131I treatment, as well as 1,3,7,14,21, and 28 days, and 2,3, and 6 months after therapy. Results: 8-epi-PGF2α showed a significant 131I dose-dependent temporary increase. The alterations were comparable in all investigated patients and significantly higher in cigarette smokers. TXB2 and 6-oxo-PGF1α showed a dose-dependent increase too. TXB 2 was higher in cigarette smokers and 6-oxo-PGF1α lower as compared to non-smokers. Conclusion: These results clearly demonstrate a dose- and time-dependent tissue (TXB2, 6-oxo-PGF 1α) and oxidation injury (8-epi-PGF2α) after 131I-therapy in the salivary glands.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
